Send me real-time posts from this site at my email

Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail

Regeneron Pharmaceuticals, Inc. REGN announced that its phase III outcomes trial on REGEN-COV (casirivimab with imdevimab) in high-risk non-hospitalized COVID-19 patients was successful.

The study evaluated the company’s investigational cocktail antibody, REGEN-COV, in infected non-hospitalized patients (n=4,567).

The study met its primary endpoint, showing that the investigational REGEN-COV significantly reduced the risk of hospitalization or death by 70% (1,200 mg intravenous [IV]) and 71% (2,400 mg IV) compared to placebo. REGEN-COV also met all secondary endpoints in the phase III outcomes trial, including the ability to reduce symptom duration.

Separately, a companion dose-ranging phase II study of 803 outpatient COVID-19 patients was conducted to evaluate the antiviral effect of several different REGEN-COV doses (IV: 2,400 mg, 1,200 mg, 600 mg and 300 mg; SC: 1,200 mg and 600 mg). All tested doses met the primary endpoint, rapidly and significantly reducing patients' viral load. Each dose demonstrated similar efficacy, including the lowest doses tested (IV: 300 mg; SC: 600 mg).

Based on these encouraging data, Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to the Emergency Use Authorization.

These phase III data will also form the basis for a full Biologics License Application.

We remind investors that REGEN-COV received an EUA from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in adults as well as pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization.

Regeneron’s shares have gained 3.8% in the past year compared with the industry’s growth of 18.5%.


Data published earlier also showed that the REGEN-COV antibody cocktail is effective against the SARS-CoV-2 variants.

Regeneron has a collaboration agreement with Roche RHHBY for REGEN-COV outside the United States.

Given the alarming levels of the spread and severity of the pandemic, quite a few pharma/biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective enough to treat the infected patients. The emerging new strains pose a greater threat.

Earlier, Vir Biotechnology, Inc. VIR and partner GlaxoSmithKline plc GSK announced that an Independent Data Monitoring Committee (IDMC) has recommended that its late-stage study evaluating VIR-7831 (GSK4182136) as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization should pause enrollment due to evidence of profound efficacy.

Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Roche Holding AG (RHHBY): Get Free Report
GlaxoSmithKline plc (GSK): Get Free Report
Vir Biotechnology, Inc. (VIR): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue